Abstract:In polypharmacology, ideal drugs are required to bind to multiple specific targets to enhance efficacy or to reduce resistance formation. Although deep learning has achieved breakthrough in drug discovery, most of its applications only focus on a single drug target to generate drug-like active molecules in spite of the reality that drug molecules often interact with more than one target which can have desired (polypharmacology) or undesired (toxicity) effects. In a previous study we proposed a new method named DrugEx that integrates an exploration strategy into RNN-based reinforcement learning to improve the diversity of the generated molecules. Here, we extended our DrugEx algorithm with multi-objective optimization to generate drug molecules towards more than one specific target (two adenosine receptors, A 1 AR and A 2A AR, and the potassium ion channel hERG in this study). In our model, we applied an RNN as the agent and machine learning predictors as the environment , both of which were pre-trained in advance and then interplayed under the reinforcement learning framework. The concept of evolutionary algorithms was merged into our method such that crossover and mutation operations were implemented by the same deep learning model as the agent . During the training loop, the agent generates a batch of SMILES-based molecules. Subsequently scores for all objectives provided by the environment are used for constructing Pareto ranks of the generated molecules with non-dominated sorting and Tanimoto-based crowding distance algorithms. Here, we adopted GPU acceleration to speed up the process of Pareto optimization. The final reward of each molecule is calculated based on the Pareto ranking with the ranking selection algorithm. The agent is trained under the guidance of the reward to make sure it can generate more desired molecules after convergence of the training process. All in all we demonstrate generation of compounds with a diverse predicted selectivity profile toward multiple targets, offering the potential of high efficacy and lower toxicity.

Enabling late-stage drug diversification by high-throughput experimentation with geometric deep learning

Late-Stage Diversification of Natural Products

Streamlining Computational Fragment-Based Drug Discovery Through Evolutionary Optimization Informed by Ligand-Based Virtual Prescreening

Identifying opportunities for late-stage C-H alkylation with high-throughput experimentation and in silico reaction screening

Predictive Minisci late stage functionalization with transfer learning

Electrocatalyzed Direct Arene Alkenylations Without Directing Groups for Selective Late-Stage Drug Diversification.

Fragment-Based Ligand Generation Guided By Geometric Deep Learning On Protein-Ligand Structure

DrugDiff - small molecule diffusion model with flexible guidance towards molecular properties

Automated design of multi-target ligands by generative deep learning

Geometric Deep Learning for Structure-Based Ligand Design

Late-stage modification of bioactive compounds: Improving druggability through efficient molecular editing

An open unified deep graph learning framework for discovering drug leads

Towards Global Feasibility Prediction and Robustness Estimation of Organic Chemical Reactions with High Throughput Experimentation Data and Bayesian Deep Learning

Deep Generative Design with 3D Pharmacophoric Constraints

Diversity oriented Deep Reinforcement Learning for targeted molecule generation

Optimizing Drug Design by Merging Generative AI With Active Learning Frameworks

Predicting Three-Component Reaction Outcomes from 40k Miniaturized Reactant Combinations

An Automated Dual Modeling Approach to Accelerate Reaction Analysis and Optimization

Traversing Chemical Space with Active Deep Learning: A Computational Framework for Low-data Drug Discovery

DrugEx V2: De Novo Design of Drug Molecules by Pareto-based Multi-Objective Reinforcement Learning in Polypharmacology

Structure-based drug design with geometric deep learning